TB-500

Mechanism of Action

Thymosin beta-4 (Tβ4) is an endogenous 43-amino acid peptide encoded by the TMSB4X gene (X-chromosome), expressed ubiquitously across mammalian tissues and present at high concentrations in platelets, macrophages, and wound fluid. It belongs to the beta-thymosin family, a group of small actin-monomer-sequestering proteins first characterised for their role in regulating the intracellular pool of G-actin (globular, unpolymerised actin monomers). TB-500 is a synthetic peptide corresponding to this same 43-amino acid sequence. In most research and commercial contexts, the name "TB-500" is used interchangeably with synthetic thymosin beta-4 and generally refers to the full 43-amino acid sequence rather than a truncated fragment, though certain research protocols specifically examine the active tetrapeptide core Ac-SDKP (N-acetyl-seryl-aspartyl-lysyl-proline), which is released enzymatically from the N-terminus of Tβ4 by prolyl oligopeptidase.

The primary molecular function of Tβ4/TB-500 is the sequestration of G-actin monomers. The central actin-binding domain, comprising approximately residues 17–23 (the LKKTET/LKKTNT sequence and flanking regions), binds actin in a 1:1 stoichiometric ratio with high affinity (Kd approximately 0.5 µM). By maintaining a large intracellular pool of unpolymerised G-actin, Tβ4 regulates the availability of actin monomers for filament elongation at the barbed ends of F-actin networks. This G-actin/F-actin equilibrium is critical for cell motility: cell migration requires localised polymerisation of actin filaments at the leading edge of migrating cells, and this process is gated by the local availability of G-actin monomers. Tissues that must rapidly mobilise migratory cells — particularly during wound repair — are critically dependent on this regulatory mechanism.

Beyond actin sequestration, TB-500 promotes cell migration and differentiation through actin-independent mechanisms. Tβ4 has been shown to translocate to the nucleus, where it associates with the promoter region of the MRTF-A (myocardin-related transcription factor A, also known as MAL/MKL1) gene and influences SRF (serum response factor)-driven transcription of cytoskeletal and repair genes. Nuclear Tβ4 function is thought to contribute to fibroblast activation and myofibroblast differentiation during tissue remodelling.

Vascular endothelial growth factor (VEGF) upregulation represents a well-documented downstream effect of Tβ4. In wound healing and ischaemia models, Tβ4 treatment increases VEGF mRNA and protein, stimulating angiogenesis — the formation of new capillary networks — in the wound bed and ischaemic tissue. This effect is partly mediated through Tβ4's interaction with integrin-linked kinase (ILK) and downstream activation of AKT/PKB, which stabilises HIF-1α (hypoxia-inducible factor 1-alpha) and drives HIF-1α-dependent VEGF transcription. This pathway is distinct from BPC-157's primarily nitric oxide and growth factor receptor-dependent wound healing mechanisms, underscoring that TB-500 and BPC-157 operate through fundamentally different molecular routes.

Anti-inflammatory effects are mediated in part through the Ac-SDKP tetrapeptide released from the Tβ4 N-terminus. Ac-SDKP inhibits NF-κB activation and downstream pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) in macrophages and dendritic cells. It also reduces TGF-β1 expression in fibrotic models and suppresses collagen I deposition by hepatic stellate cells and cardiac fibroblasts. These anti-fibrotic properties of Ac-SDKP are well characterised in cardiovascular and renal fibrosis models and may explain much of TB-500's reported benefit in post-injury tissue remodelling contexts.

Pharmacokinetics

Formal pharmacokinetic characterisation of TB-500 in humans does not exist in the peer-reviewed literature. Animal pharmacokinetic data indicate that following subcutaneous or intraperitoneal injection of synthetic Tβ4, plasma peptide concentrations peak within 1–4 hours and decline with a half-life of approximately 2–4 hours. Tissue distribution studies in rodents show accumulation in wound sites, consistent with the peptide's role in tissue repair, as well as in heart, kidney, and liver. Distribution to the CNS has been reported in rodent models of neurological injury, likely reflecting BBB compromise at sites of inflammation.

Tβ4/TB-500 is degraded primarily through proteolysis by prolyl oligopeptidase (which cleaves the N-terminal Ac-SDKP fragment) and through nonspecific peptidases in plasma and tissue. The Ac-SDKP fragment itself has distinct pharmacological activity and a shorter half-life; its contribution to the in vivo effects of exogenous TB-500 is likely significant but incompletely characterised. Renal clearance of intact peptide and fragments occurs, though given the short half-life this is not the rate-limiting step. No information on drug-drug interaction via CYP450 is applicable, as TB-500 is a peptide substrate for proteases rather than a CYP450 substrate.

Intramuscular administration is used interchangeably with subcutaneous in most research contexts; bioavailability differences between these routes are not formally characterised. Intravenous administration has been used in cardiac trial contexts (the RegeneRx programme). Oral bioavailability is negligible due to gastrointestinal peptide degradation.

Reported Effects

Primary Research Findings

• Wound closure (rodent skin models): Multiple studies from the Goldstein and Bhatt groups demonstrated accelerated dermal wound closure in full-thickness excisional wounds in mice and rats treated with Tβ4/TB-500 at 150–500 mcg/kg intraperitoneally or subcutaneously. Histological analysis confirmed more organised collagen deposition and increased vascularity in treated wounds.
• Corneal wound healing: Tβ4 has been extensively studied for corneal epithelial wound healing. Topical thymosin beta-4 eye drops accelerate re-epithelialisation in rodent and rabbit corneal injury models. This led directly to Phase I/II clinical trials conducted by RegeneRx Biopharmaceuticals (see Clinical Evidence section).
• Cardiac repair (ischaemia-reperfusion): Heart attack models in mice (Bock-Marquette et al., Nature 2004) demonstrated that Tβ4 treatment of infarcted myocardium mobilised endogenous cardiac progenitor cells and reduced cardiomyocyte apoptosis, improving ejection fraction and ventricular dimensions. The mechanism involves ILK activation and AKT phosphorylation in cardiomyocytes.
• Tendon healing: Rat tendon transection models showed improved mechanical properties (tensile strength, failure load) and histological organisation in Tβ4-treated tendons versus vehicle at 4–8 weeks post-injury. Increased type I collagen and reduced inflammatory infiltrate were noted.
• Anti-inflammatory activity in multiple tissue types: Suppression of macrophage pro-inflammatory cytokine production (TNF-α, IL-1β, IL-6) and NF-κB nuclear translocation has been demonstrated consistently in cell culture and in multiple in vivo models.

Secondary / Emerging Findings

• Neurological injury: In rodent TBI and spinal cord injury models, Tβ4 treatment has been associated with reduced lesion volume, improved neurological deficit scores, and upregulation of neurotrophic factors in perilesional tissue. These findings are preliminary.
• Hair follicle activation: Tβ4 has been reported to accelerate hair follicle entry into the anagen (active growth) phase in murine models, with topical application showing effects. The mechanism may involve Wnt/β-catenin pathway activation in follicle stem cells.
• Renal and hepatic anti-fibrosis: Ac-SDKP, the enzymatic cleavage product, shows anti-fibrotic effects in angiotensin II-driven renal fibrosis models, reducing interstitial collagen accumulation. These findings with the Tβ4 fragment Ac-SDKP may partly translate to effects of exogenous TB-500 administration.
• Angiogenesis in ischaemic limb models: Intramuscular TB-500 in hindlimb ischaemia models increases capillary density and improves perfusion measurements, consistent with VEGF upregulation.

Effects Not Yet Demonstrated in Humans

The cardiac progenitor cell mobilisation and myocardial repair findings from Bock-Marquette et al. (2004) were highly cited and generated substantial interest in Tβ4 as a cardiac regenerative therapy. However, the human cardiac Phase I/II trials conducted by RegeneRx (RGN-352) have not produced published Phase III data demonstrating clinically meaningful improvement in cardiac outcomes. The translation from rodent myocardial infarction models to human clinical benefit has not been confirmed.

The tendon, ligament, and musculoskeletal repair benefits — the primary reason TB-500 attracts interest in athletic and recovery contexts — have not been evaluated in any registered human clinical trial. All data in these domains comes from rodent models. Extrapolation to human musculoskeletal repair is biologically plausible given conserved wound healing mechanisms but is not empirically established.

Dosing & Administration

No FDA-approved or EMA-approved dosing regimen exists for TB-500 for any subcutaneous use. The following reflects pre-clinical data and research community practice only; no human efficacy dose has been established.

Loading phase (weeks 1–6): Research community practice most commonly describes 2–2.5 mg subcutaneously two times per week during a loading phase, for a weekly total of 4–5 mg. This phase is intended to build up tissue concentrations during active injury recovery or cycle initiation. Some protocols extend the loading phase to eight weeks for severe or chronic injuries.

Maintenance phase (weeks 7 onwards): Following the loading phase, dose reduction to 2 mg once weekly is commonly described for ongoing tissue maintenance or continued recovery support.

Route: Subcutaneous injection is standard in research practice. Intramuscular administration is used interchangeably by some researchers; no formal bioavailability comparison between SubQ and IM for TB-500 exists. Intravenous administration was used in the RegeneRx cardiac trials and is not relevant to musculoskeletal research use.

Reconstitution and storage: TB-500 is supplied as a lyophilised powder. Reconstitution with bacteriostatic water (BAC water) is standard, using 1–2 mL per vial depending on desired injection volume. Reconstituted peptide should be refrigerated at 2–8°C and used within 28–30 days. Lyophilised, unreconstituted peptide may be stored at −20°C for longer periods. Avoid repeated freeze-thaw cycles of reconstituted solution.

Pre-clinical allometric context: Rodent studies employed 100–500 mcg/kg IP or SubQ. Simple allometric scaling to a 70 kg human suggests 7–35 mg/dose — substantially higher than community practice doses. Allometric scaling of peptide bioactivity is unreliable, and community doses represent a practical lower range rather than an evidence-derived optimum.

Side Effects & Safety Profile

Commonly Observed

Injection site reactions — including mild erythema, induration, and tenderness — are the most commonly reported adverse effects with subcutaneous TB-500 administration. These are typical of peptide injections generally and are not specific to Tβ4/TB-500. In animal toxicology studies, no significant systemic toxicity was observed at doses up to 20 mg/kg, far exceeding typical research doses.

Less Common

Transient fatigue or lethargy has been reported anecdotally in research users, though this is not documented in controlled pre-clinical studies. Mild transient increases in pain at the site of existing injury have been noted by some research subjects, possibly reflecting increased cellular activity or inflammatory signalling during the early healing process.

Contraindications & Warnings

The most significant safety concern with TB-500 is not a documented adverse effect but rather the absence of human safety data. No formal Phase I pharmacokinetic or dose-escalation human safety study has been published for the subcutaneous route used in most research applications. The RegeneRx Phase I/II data for intravenous cardiac use represents the closest available human safety signal, and in those trials the compound was reported as well-tolerated at the doses tested.

Theoretical safety concerns include the promotion of angiogenesis in contexts where neovascularisation is undesirable, such as in the presence of occult malignancies. Tβ4 has been identified as upregulated in several tumour microenvironments, and its role in tumour vasculature and cancer cell migration is an active area of research with ambiguous conclusions. The Ac-SDKP fragment has been associated with both pro- and anti-tumour effects in different model systems. Until human safety studies are completed, use in individuals with active malignancy or a history of hormone-sensitive cancers should be considered contraindicated based on theoretical risk.

The purity, sterility, and peptide authenticity of commercially available TB-500 research peptides are not subject to regulatory oversight. Contamination with bacteriostatic agents, endotoxins, or misidentified sequences represents a real risk in the unregulated research peptide market.

Clinical Evidence

The human clinical evidence base for thymosin beta-4 / TB-500 is concentrated in two programmes conducted by RegeneRx Biopharmaceuticals, neither of which studied the subcutaneous musculoskeletal application that drives most research community interest.

Cardiac: RGN-352 (Thymosin Alpha Trial in Coronary artery disease, TATC) — RegeneRx conducted a Phase II trial examining IV thymosin beta-4 in patients following acute coronary syndrome. Results reported at conference indicated acceptable safety but only modest, non-statistically significant improvements in cardiac function parameters including ejection fraction and ventricular dimensions. The trial did not progress to Phase III. The mechanistic basis — ILK-AKT activation, reduced cardiomyocyte apoptosis, progenitor cell mobilisation — was well-supported by Bock-Marquette et al. (Nature, 2004), but translation from the mouse infarction model to clinical human benefit proved elusive, a pattern seen across many cardiac regenerative peptides.

Ophthalmic: RGN-259 — Phase II trials (ARISE-1 and ARISE-2) examined topical Tβ4 eye drops for dry eye syndrome and neurotrophic keratitis. ARISE-1 demonstrated statistically significant improvements in symptom scores and corneal staining; ARISE-2 results were mixed. Neither programme was advanced to Phase III.

TB-500's distinct status from full-length Tβ4 matters here. TB-500 in most commercial research contexts refers to the same 43-amino acid sequence as Tβ4; however, no pharmacokinetic or clinical trial has specifically studied the synthetic research peptide product marketed as "TB-500" in the subcutaneous route. The animal literature — Malinda et al. (FASEB J, 1997) for wound healing, multiple groups for tendon and cardiac repair, Sosne et al. for corneal healing — is mechanistically robust and internally consistent, but no registered human trial has investigated subcutaneous TB-500 for tendon, ligament, muscle, or musculoskeletal repair in any population.

Evidence grade: C for the subcutaneous musculoskeletal use case. Evidence grade B for mechanism and pre-clinical data, with limited Phase I/II human data restricted to ophthalmic and IV cardiac contexts.

Interaction Considerations

No formal drug-drug interaction studies for TB-500 have been conducted. The following considerations apply based on mechanism:

• Anticoagulants and antiplatelet agents: Tβ4 is present at high concentrations in platelets and plays a role in platelet activation; the interaction with drugs affecting coagulation (warfarin, heparin, aspirin, clopidogrel) has not been formally evaluated.
• Corticosteroids: Corticosteroids suppress wound healing through anti-inflammatory mechanisms. TB-500 and corticosteroids are potentially antagonistic in wound repair contexts, though this has not been formally tested.
• BPC-157: Frequently combined in research and athletic recovery contexts. While both peptides promote tissue repair, they do so through distinct molecular mechanisms (actin dynamics/VEGF for TB-500; nitric oxide and growth factor receptor pathways for BPC-157), and no interaction study or controlled combination trial exists. Additive benefit is biologically plausible, but combination safety is not characterised.
• Angiogenic compounds: TB-500 upregulates VEGF; combining with other pro-angiogenic compounds (e.g., VEGF-containing biologics, certain peptide growth factors) could theoretically produce excessive neovascularisation.

Discovery & Research Timeline

• 1966 — Allan Goldstein and Abraham White at the Albert Einstein College of Medicine begin characterising thymic hormones; thymosin fraction 5 is first isolated from bovine thymus.
• 1977 — Thymosin beta-4 isolated as a distinct component of thymosin fraction 5, characterised as a small acidic polypeptide present in high abundance in thymic tissue and platelets.
• 1981 — Complete 43-amino acid sequence of thymosin beta-4 determined. Molecular weight established as approximately 4,964 Da.
• Late 1980s–1990s — Actin-sequestering function identified by Safer and colleagues; Tβ4 established as the primary G-actin-binding protein in non-muscle cells. Stoichiometry of 1:1 Tβ4:G-actin binding characterised.
• 1991 — Hannappel and colleagues demonstrate Tβ4 is the most abundant actin-binding peptide in mammalian cells, challenging previous assumptions about profilin's dominance.
• 1997 — Malinda et al. (FASEB J) demonstrate that Tβ4 accelerates wound closure in rodent skin wound models. This pivotal study opens the wound healing research programme.
• 2004 — Bock-Marquette et al. (Nature) publish landmark findings showing Tβ4 treatment of infarcted mouse hearts reduces cardiomyocyte death and improves cardiac function. This paper drives the RegeneRx cardiac trials.
• 2004–2010 — RegeneRx Biopharmaceuticals conducts Phase I and Phase II trials in cardiac indications (RGN-352) and corneal healing (RGN-259).
• 2005–2010 — Pre-clinical data accumulates for tendon, ligament, muscle, and neurological healing in rodent and equine models.
• 2007 — Goldstein and colleagues characterise the nuclear translocation of Tβ4 and its transcriptional roles in MRTF-SRF signalling, expanding the understanding beyond actin sequestration.
• 2010s — Equine and canine veterinary studies on tendon repair (notably in horse tendon injury models) generate data that influences human research community interest. TB-500 enters research peptide markets.
• 2014–2019 — ARISE-1 and ARISE-2 Phase II trials with RGN-259 ophthalmic solution for dry eye. Mixed outcomes.
• 2020–present — Continued mechanistic research; no progression to Phase III for any Tβ4 indication. Research community use for musculoskeletal recovery continues without formal clinical validation.

Research Disclaimer

The information presented in this article is compiled from pre-clinical literature, limited Phase I/II clinical trial reports, and mechanistic studies for educational and research purposes. TB-500 (synthetic thymosin beta-4) is not approved by the FDA, EMA, or any major regulatory agency for subcutaneous injection for musculoskeletal repair, injury recovery, or any other indication in humans. The human clinical trial data that exists is restricted to topical ophthalmic and intravenous cardiac formulations in specific patient populations. All musculoskeletal and athletic recovery applications discussed in the research community literature are based entirely on animal model data. The absence of human pharmacokinetic, safety, and efficacy data for the subcutaneous route represents a fundamental gap that cannot be bridged by animal study extrapolation alone. This article does not constitute medical advice, a diagnosis, or a treatment recommendation. Researchers using this compound should independently verify purity and sterility of their source material, as research peptide quality is not regulated to pharmaceutical standards.

---

Build Your Personalised Protocol

TB-500 is one of many compounds available in the BioStack Generator. Explore repair and recovery stacks alongside other peptide compounds.

Get Your BioStack →